La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Peak Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Peak Bio..

Peak Bio (OTC:PKBO) Azioni, Catena delle Opzioni

Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology, inflammation and rare diseases.

Peak Bio Inc

Sony Group Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) leadership discussed the abrupt closure of Concord, a live-service shooter launched just this August and pulled only 11 days later due to<a href="https://www.benzinga.com/general/gaming"> low sales. </a>
<h3 class="wp-block-heading">An Eye-Opening Setback For Sony's Live Service Ambitions</h3>
Speaking during a a recent earnings call (<a href="https://www.gamesindustry.biz/sony-on-concords-failure-with-new-ip-you-dont-know-the-result-until-you-actually-try-it">via</a> GamesIndustry.biz), Sony's president, COO, and CFO Hiroki Totoki acknowledged that Sony is still navigating the complexities of live-service games—a sector where it remains relatively inexperienced. Totoki noted that internal reviews have already highlighted key areas for improvement.
See Also: <a href="https://www.benzinga.com/markets/equities/24/09/40711249/sony-pulls-plug-on-concord-multiplayer-shooter-game-goes-offline-soon-after-launch">Sony Pulls Plug On Concord: Multiplayer Shooter Game Goes Offline Soon After Launch</a>
"With regards to new IP, of course, you don't know the result until you actually try it," Totoki explained through an interpreter. "We probably need to have a lot of gates, including user testing or internal evaluation, and the timing of such gates. And then we need to bring them forward, and we should have done those gates much earlier than we did."
The approach to Concord, a new IP managed by Firewalk Studios, is a case in point. Totoki pointed out that Sony&#8217;s organizational structure, which he described as "siloed," complicated collaboration across development and sales. Breaking down these barriers, he suggested, could enable smoother game rollouts and stronger sales alignment.
The platform holder has also recognized the importance of timing in live-service game launches. Totoki pointed out that selecting the optimal release window is critical — not only for a title&#8217;s success but also for preventing "cannibalization" across Sony&#8217;s portfolio.
<h3 class="wp-block-heading">Aftermath: Refunds, Studio Closure, And Corporate Lessons</h3>
Following Concord&#8217;s short-lived journey, Sony offered players full refunds and announced the closure of Firewalk Studios. 
Sadahiko Hayakawa, Sony's senior vice president for finance and investor relations, contrasted Concord&#8217;s trajectory with the company's other live-service launch this year, Helldivers 2, which he described as "a huge hit." 
According to Hayakawa, both launches provided invaluable insights into managing live-service games and highlighted the need for Sony to fine-tune its development strategies.
"We intend to share the lessons learned from our successes and failures across our studios, including in the areas of title development management as well as the process of continually adding expanded content and scaling the service after its release so as to strengthen our development management system," Hayakawa stated.
<h3 class="wp-block-heading">Forging Ahead With A Balanced Portfolio Of Live And Single-Player Games</h3>
Despite Concord&#8217;s challenges, Sony remains committed to expanding its live-service lineup. In 2023, the company set an ambitious goal to launch six live-service titles by the end of March 2026. 
To balance its portfolio, Sony plans to leverage its strength in single-player games—often more predictable hits due to established IPs—alongside live-service ventures that may involve greater risk but promise lucrative returns if successful.
Hayakawa said that Sony aims to develop "an optimum title portfolio during the current mid-range plan period that combines single-player games — which are our strengths and which have a higher predictability of becoming hits due to our proven IP — with live-service games that pursue upside while taking on a certain amount of risk upon release."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41856199/ps5-surpasses-65-million-sales-hardware-slows">PS5 Surpasses 65 Million Sales, Hardware Slows</a></li>
</ul>
Image courtesy: Sony

Entertainment

Gaming

News

General

Sony Group Corporation American Depositary Shares

SONY

'You Don't Know The Result Until You Actually Try It': Sony CEO On Concord's 11-Day Shutdown

FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) reported quarterly losses of $(0.03) per share. This is a 150 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $55.10 million in sales this quarter. This is a 52.81 percent decrease over sales of $116.75 million the same period last year.

Earnings

FutureFuel Q3 EPS $(0.03) Down From $0.06 YoY, Sales $55.10M Down From $116.75M YoY

Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.53 by 13.21 percent. The company reported $938.40 million in sales this quarter. This is a 4.05 percent increase over sales of $901.87 million the same period last year.

Earnings Misses

Hawaiian Electric Indus Q3 2024 Adj EPS $0.46 Misses $0.53 Estimate, Sales $938.40M Up From $901.87M YoY

Following Donald Trump&#8216;s election victory, stocks of companies focused on reshoring production to the U.S. surged sharply this week, driven by expectations of <a href="https://www.benzinga.com/topic/donald-trump">more protectionist policies.</a>
The American Reshoring ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSHO#NYSE">RSHO</a>)—a fund investing in 30 companies committing to reshoring their production lines back home—jumped over 8% in the week, outpacing broader market indices. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 5% and on par with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>).
<h3 class="wp-block-heading">Why Expert Sees A Reshoring Boom Ahead</h3>
Trump&#8217;s win has reignited investor optimism around reshoring, with policies likely to push U.S. companies to prioritize domestic production over cheaper overseas options.
"The case for reshoring is now well set with the Trump presidency," said Maurits Pots, CEO of Tema ETFs, in an exclusive Benzinga interview.
The new administration is expected to support trade protectionism and tariff increases, a strategy Maurits emphasized as a "key driver of reshoring and domestic manufacturing growth." 
"Companies used to think about what was my lowest cost of production," Pots said. "Now they're asking, ‘where can I get more secure, closer-to-home production?' Security in supply chains is increasingly outpacing cost in importance," he added. 
This shift towards U.S.-centered manufacturing appears to reflect market anticipation that the administration will implement policies with a "primarily U.S. focus," especially after the potential of a red sweep.
Heavy equipment manufacturers, often seen as bellwethers for industrial sentiment, were among the big winners this week. Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) rose more than 8% post-election, signaling investors' heightened interest in U.S. industrial stocks.
Maurits highlighted a similar trend with equipment companies, such as Terex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) .
He noted that these stocks "had very strong moves recently, indicating that expectations of a reacceleration in American capex will be a focus point for the administration."
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a>
<h3 class="wp-block-heading">Trade Policies: Tariffs, Subsidies, And The Mexico &#8216;Nearshoring&#8217; Risk</h3>
"We believe tariffs may ultimately prove less harsh than threatened," said Pots, "but the mere uncertainty around tariffs will itself already form a catalyst for reshoring as companies increasingly value supply chain security and stability."
According to Pot, the Trump administration's stance could also discourage "nearshoring" — the trend of moving production closer to the U.S., but not quite on its soil, such as to Mexico. 
With Trump's proposed tariffs on Mexican goods, Mexico's appeal as a manufacturing hub may diminish, further driving interest in truly domestic production.
Interestingly, Pot highlighted that most of the reshoring incentives introduced during the Biden administration, including substantial investment packages like the CHIPS Act, have been concentrated in Republican-led states. 
This aspect of the fund distribution could protect these initiatives from potential rollback under Trump, as they align with his administration's agenda of strengthening U.S. manufacturing.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41848568/us-consumer-sentiment-rises-more-than-predicted-to-6-month-highs-inflation-expectations-hit-4-year-low">US Consumer Sentiment Rises More Than Predicted To 6-Month Highs, Inflation Expectations Hit 4-Year Low</a></li>
</ul>
Photo: Shutterstock

Large Cap

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Politics

Small Cap

Global

Econ #s

Exclusives

Interview

ETFs

Tema ETF Trust Tema American Reshoring ETF

RSHO

EXCLUSIVE: Trump Victory Triggers 'Reshoring' Rally As Supply Chain Security Outweighs Cost

<h3>Gainers</h3>
<ul>
<li>CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) stock rose 13.9% to $38.0 during Friday's pre-market session. The market value of their outstanding shares is at $3.9 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) shares increased by 11.33% to $13.06. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Kuke Music Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) shares rose 11.11% to $0.46. The market value of their outstanding shares is at $18.1 million. </li>
<li>Gray Television (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) shares increased by 9.89% to $8.33. The company's market cap stands at $830.2 million. The company's, Q3 earnings came out today. </li>
<li>AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) stock rose 8.98% to $9.1. The market value of their outstanding shares is at $401.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Lytus Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) shares moved upwards by 7.87% to $1.78. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gray Television (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) shares fell 16.2% to $4.85 during Friday's pre-market session. The company's market cap stands at $483.3 million. The company's, Q3 earnings came out today. </li>
<li>Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) stock declined by 13.95% to $29.2. The company's market cap stands at $20.0 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) stock declined by 12.71% to $115.69. The market value of their outstanding shares is at $56.8 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Fangdd Network Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) stock fell 12.32% to $1.21. The market value of their outstanding shares is at $16.3 million. </li>
<li>DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) stock declined by 7.19% to $14.85. The company's market cap stands at $735.8 million. </li>
<li>Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) shares decreased by 7.05% to $2.64. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q3 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMCX

CARG

KIND

KUKE

PINS

WBTN

12 Communication Services Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 75.3% to $0.46 during Friday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock rose 29.94% to $56.42. The company's market cap stands at $10.4 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock rose 26.31% to $22.8. The market value of their outstanding shares is at $2.0 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares moved upwards by 20.39% to $3.01. The company's market cap stands at $237.4 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock rose 15.11% to $1.37. The company's market cap stands at $13.9 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares rose 14.99% to $1.15. The company's market cap stands at $89.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock declined by 51.8% to $0.69 during Friday's pre-market session. The company's market cap stands at $13.1 million. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) stock decreased by 40.06% to $4.7. The market value of their outstanding shares is at $665.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 38.75% to $15.05. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock fell 33.34% to $1.86. The market value of their outstanding shares is at $765.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 29.7% to $0.69. The market value of their outstanding shares is at $79.6 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 25.61% to $4.3. The company's market cap stands at $447.9 million. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVR

CTMX

DOCS

FTRE

INDP

MRVI

PRPH

RVNC

TIVC

TNYA

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares increased by 175.6% to $0.62 during Friday's pre-market session. The company's market cap stands at $17.9 million. </li>
<li>Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) stock rose 37.95% to $4.98. The company's market cap stands at $115.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) stock moved upwards by 24.11% to $30.21. The market value of their outstanding shares is at $875.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares rose 17.39% to $0.3. The company's market cap stands at $8.7 million. </li>
<li>Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) stock rose 15.15% to $539.78. The market value of their outstanding shares is at $40.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) stock increased by 12.86% to $17.55. The market value of their outstanding shares is at $1.5 billion. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nature's Miracle Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) shares decreased by 29.7% to $0.1 during Friday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>CDT Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares declined by 24.82% to $3.03. The company's market cap stands at $32.4 million. </li>
<li>Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) shares decreased by 15.43% to $1.7. The market value of their outstanding shares is at $171.9 million. The company's, Q3 earnings came out yesterday. </li>
<li>Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) stock fell 14.16% to $50.59. The company's market cap stands at $8.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) stock fell 13.49% to $5.84. The company's market cap stands at $17.6 million. </li>
<li>Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) shares decreased by 12.61% to $8.11. The company's market cap stands at $134.8 million. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXON

BLNK

CDTG

ELWS

INOD

LICY

Nuveen Insured California Premium Fund Ii

NMHI

SOAR

TASK

ULBI

12 Industrials Stocks Moving In Friday's Pre-Market Session

WIIM

TVGN

Tevogen Bio Holdings shares are trading higher after the company announced it is near the finalization of an agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities. Also, the company reaffirmed its existing agreements which provides access to a $36 million line of credit.

<h3>Gainers</h3>
<ul>
<li>Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares increased by 34.9% to $4.63 during Friday's pre-market session. The company's market cap stands at $830.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>EMCORE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMKR#NASDAQ">EMKR</a>) shares increased by 28.69% to $3.05. The company's market cap stands at $27.6 million. </li>
<li>Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares increased by 27.84% to $2.98. The market value of their outstanding shares is at $299.2 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) shares rose 24.5% to $40.85. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) shares increased by 18.36% to $78.0. The market value of their outstanding shares is at $8.0 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares rose 16.78% to $86.0. The company's market cap stands at $5.8 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) stock fell 18.2% to $12.78 during Friday's pre-market session. The company's market cap stands at $1.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares fell 18.1% to $9.96. The company's market cap stands at $995.3 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) shares declined by 17.18% to $3.23. The market value of their outstanding shares is at $121.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) stock decreased by 16.56% to $12.25. The company's market cap stands at $589.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) stock decreased by 12.25% to $12.53. The market value of their outstanding shares is at $1.8 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) shares declined by 9.24% to $1.77. The company's market cap stands at $20.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARLO

BILL

CCTG

CMPO

EMKR

FIVN

INDI

LASR

LITE

LTRX

PRCH

SEMR

12 Information Technology Stocks Moving In Friday's Pre-Market Session

NPABU

Trading Halt: Halted at 4:04:29 p.m. ET - Trading Halt: Halt News Pending

NPAB

NPABW

U.S. federal authorities have disclosed an assassination plot by Iranian operatives, targeting <a href="https://www.benzinga.com/topic/donald-trump">former President Donald Trump. </a>
The plan, unveiled on Friday, involved recruiting criminal assets to monitor and ultimately kill him on American soil, the AP News <a href="https://apnews.com/article/iran-fbi-justice-department-iran-83cff84a7d65901a058ad6f41a564bdb">reports</a>.
What Happened: The Justice Department released details of the plot following the indictment of Farhad Shakeri, an alleged Iranian government operative. Shakeri reportedly received orders from Iran&#8217;s Revolutionary Guard to organize surveillance on Trump and prepare for a possible assassination attempt, per federal court filings. 
The instructions reportedly came with an urgent seven-day deadline. Authorities stated that Shakeri's handlers implied the operation would be easier if Trump lost the election, expecting a potential delay if he remained in office, the AP reports. 
Shakeri remains at large in Iran, while two other suspects linked to separate Iranian-backed assassination schemes have been apprehended. 
Also Read: <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">Trump Says He Won&#8217;t Sell Trump Media Stock</a>
According to the Department of Justice, Tehran's attempts to disrupt the U.S. political landscape have included both physical threats and cyber operations. A previous incident involved Iranian hackers attempting to distribute stolen Trump campaign data to Joe Biden's team. Intelligence sources confirmed that no response came from Biden's camp <a href="https://www.benzinga.com/news/24/09/40933501/us-intel-agencies-reveal-iran-tried-to-share-hacked-trump-campaign-data-with-team-biden-fbi-says-no">regarding these phishing attempts.</a>
Why It Matters: This assassination plot is part of a broader Iranian strategy to challenge and destabilize American security. Following the high-profile killing of Gen. Qassem Soleimani under Trump's orders, Iranian leaders pledged retribution, intensifying hostile operations against U.S. figures, according to the AP.
Attorney General Merrick Garland, addressing these developments, reiterated that Iran's provocative actions remain a grave concern for U.S. national security. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a></li>
</ul>
Photo: Shutterstock

Iranian Plot Against Trump Unveiled As Tensions With US Grow

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.19) by 68.91 percent.

Earnings Beats

APTO

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

This year's MJBizCon in Las Vegas promises to deliver crucial insights from industry pioneers, with two key panels featuring <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis'</a> managing director <a href="https://www.benzinga.com/author/javier-hasse">Javier Hasse</a>, along with renowned voices in the cannabis sector. These sessions will provide actionable knowledge for entrepreneurs and investors navigating the burgeoning cannabis industry, including pivotal discussions on brand building and the rapid evolution of Latin American cannabis markets.
<h3 class="wp-block-heading">Embracing Your Brand's Unique Magic: How To Build An Iconic Brand In The Ancillary Market</h3>
Date &amp; Time: Wednesday, December 4, 2024, 2:00pm – 2:40pm Location: Room 2 &#8211; Cannabis Business 101
In this session, cannabis branding is the focal point, led by <a href="https://www.benzinga.com/markets/cannabis/24/08/40140453/how-a-simple-magic-trick-led-to-one-of-the-most-recognized-cannabis-related-brands-in-the-world-">Josh Kesselman</a>, CEO and founder of <a href="https://www.benzinga.com/markets/cannabis/24/07/40076950/raw-rolling-papers-are-not-drug-paraphernalia-court-confirms">RAW Rolling Papers</a>, a globally recognized brand rooted in authenticity and simplicity. Known for his unfiltered approach, Kesselman's journey—from opening a smoke shop to founding a major brand—demonstrates the power of authenticity in establishing a loyal customer base.
For those exploring opportunities in the cannabis ancillary market, Kesselman's insights will be invaluable. As he explains, the ancillary market remains a fertile ground for entrepreneurs free from stringent regulations that often accompany cannabis itself. Topics include unconventional marketing approaches and how to leverage technology and security to amplify brand presence. 
Javier Hasse's expertise in content and cannabis market growth adds an additional layer, with his experience shaping media narratives for both Benzinga and <a href="https://elplanteo.com/">El Planteo</a>. This panel invites entrepreneurs to think innovatively in a field where standing out is essential.
<h3 class="wp-block-heading">Cannabis In Latin America: Market Evolution And Opportunities</h3>
Date &amp; Time: Friday, December 6, 2024, 10:00am – 10:40am Location: Room N110 &#8211; International Regulatory Roundup
As cannabis markets continue to expand in Latin America, this panel explores the region's distinct landscape. Javier Hasse will join a discussion with industry leaders, including <a href="https://www.benzinga.com/markets/cannabis/24/06/39114436/how-3-chilean-brothers-built-a-global-cannabis-platform-embraced-by-big-sponsors-like-adidas-and">Simón Espinosa</a>, CEO of En Volá; Julian Wilches, co-founder and CRO at Clever Leaves (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLEVER#OTC">CLEVER</a>); and Zara Snapp, director at Instituto RIA. Together, they will dissect the evolving regulatory frameworks, investment potential and unique challenges in key countries such as Argentina, Mexico, Chile and Colombia.
This conversation will provide critical insights into how regulatory and social dynamics shape opportunities in Latin America, a region gaining prominence as both a cultivator and consumer of cannabis. Espinosa's experience with En Volá offers a cultural perspective, while Wilches and Snapp bring expertise in regulatory compliance and policy reform. Attendees will walk away with a nuanced understanding of how to navigate these diverse markets, the importance of local partnerships, and strategies for sustainable growth amid complex regulations.
More details <a href="https://mjbizconference.com/">here</a>.

Cannabis

Legal

Events

CLEVER

Josh Kesselman, Javier Hasse And More Experts Dive Into Cannabis Market Trends At MJBizCon

Donald Trump's 2024 presidential election win is already having an impact on<a href="https://www.benzinga.com/general/politics/24/11/41817245/will-trump-be-sentenced-in-hush-money-trial-or-will-his-criminal-problems-go-away"> his pending court cases</a>: a federal judge paused a 2020 election interference prosecution from Special Counsel Jack Smith Friday.
What Happened: Trump's defeat of Vice President Kamala Harris in <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">the 2024 presidential election</a> will put him back in the White House in January 2025. The election win could make it possible for Trump to avoid courtrooms in the future, with pending cases likely to be dismissed and thrown out.
On Friday, U.S. District Judge Tanya Chutkan paused a case against Trump related to election interference claims. Special Counsel Jack Smith previously charged Trump with trying to remain in the White House after the 2020 election despite losing to President Joe Biden.
Smith filed to pause the proceedings and said he plans to make a filing on Dec. 2 about how the criminal case should proceed now that Trump will be president again, as reported by <a href="https://www.bloomberg.com/news/articles/2024-11-08/us-special-counsel-asks-court-to-pause-trump-prosecution?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>.
Justice Department policy prevents the current president from being prosecuted, according to the report. Smith said the case will likely be dropped due to this policy.
On Friday, Smith said in a filing that he needs "time to assess this unprecedented circumstance and determine the appropriate course going forward" due to the Department of Justice policy.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: The 2020 election interference isn't the only case impacted by Trump's 2024 win.
Trump was previously found guilty on 34 counts of falsifying business records in what is known as the hush money trial. Sentencing in the case was delayed several times by Judge Juan Merchan and a sentencing date of Nov. 26 is now in question after Trump's election victory.
As <a href="https://www.benzinga.com/general/politics/24/11/41817245/will-trump-be-sentenced-in-hush-money-trial-or-will-his-criminal-problems-go-away">Benzinga reported Thursday</a>, legal experts are skeptical that Merchan would still carry out sentencing of the future sitting president. Merchan also plans to issue a ruling by Nov. 12 on Trump's legal team's request to toss out the guilty verdict after the Supreme Court issued partial immunity to former presidents earlier this year.
Trump faces potential punishment of up to four years in prison for each guilty verdict, with a limit of 20 total years in prison. While prison time is unlikely due to his lack of a previous criminal record, Trump could receive probation or home confinement.
If Merchan chooses to continue with sentencing he would be tasked with deciding whether to defer the sentencing to 2029 when Trump is out of the White House, delay Trump's punishment until 2029 or try to place the punishment on Trump while he's in office.
A classified documents case against Trump saw the former president charged in June 2023. The case, which was also brought against Trump by Smith, is also expected to be dismissed after the election result, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-08/can-trump-go-to-jail-after-2024-election-win-whats-next-in-his-criminal-cases?itm_source=record&amp;itm_campaign=Trump_Legal_Troubles&amp;itm_content=What%27s_Next-1&amp;sref=TBDibEcD">reported</a>.
A case against Trump in the state of Georgia saw charges brought against the former president in August 2023 related to conspiracy in the 2020 election. Trump's legal team is preparing for an argument to dismiss the case due to his return to the White House.
Among the reasons legal experts expect the cases to be dropped against Trump is a fear of retaliation against the judges and lawyers involved in cases.
On Thursday, Trump ally Mike Davis issued a warning to New York Attorney General Letitia James during an appearance on "The Benny Show" podcast.
"I dare you to try to continue your lawfare against President Trump in his second term," Davis said, as <a href="https://nypost.com/2024/11/07/us-news/trump-ally-mike-davis-warns-ny-ag-letitia-james-to-back-off-president-elect/">reported </a>by the New York Post. "Listen her, sweetheart, we're not messing around this time and we will put your fat a&#8211; in prison for conspiracy against rights. I promise you that."
James won a $454 million civil fraud judgment in the state of New York related to Trump and the Trump Organization's business dealings in the state. On Wednesday, James said she would "use the rule of law to fight back" against Trump. The president-elect has appealed the ruling in New York.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">Donald Trump&#8217;s Wealth Soars With 2024 Election Win: Here&#8217;s How Much President-Elect Is Worth, How Much He&#8217;ll Make In White House</a></li>
</ul>
Photo via Shutterstock.

Trump 2020 Election Interference Case Paused: How 2024 Election Win Is Impacting President-Elect's Legal Troubles

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher Friday after climbing new highs during the week. Here&#8217;s what <a href="https://www.benzinga.com/quote/PLTR/news">you need to know.</a>
The Details: On Monday, Palantir <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">reported third-quarter revenue</a> of $725.52 million, surpassing the $701.13 million estimate and earnings per share of 6 cents, beating expectations of 4 cents. Total revenue rose 30% year-over-year, with U.S. commercial revenue up 54% and U.S. government revenue up 40%. CEO Alex Karp added that the company's growth is "driven by unrelenting AI demand that won't slow down."
Shares<a href="https://www.benzinga.com/news/earnings/24/11/41746288/palantir-stock-is-hitting-new-highs-whats-going-on"> continued to rise </a>after some analysts commented on Palantir's expanding U.S. customer base and AI product demand. Analysts at Wedbush, Mizuho and DA Davidson all raised their price targets, with Wedbush's Dan Ives citing Palantir's "robust" results and AI expansion. 
The stock hit another all-time high on <a href="https://www.benzinga.com/news/earnings/24/11/41782430/palantir-shares-are-hitting-new-highs-on-wednesday-whats-going-on">Wednesday </a>after Donald Trump's presidential win sparked market optimism on potential policy shifts, which could favor defense and AI sectors. Palantir, up 25% over the past week, was seen as a potential beneficiary of a Trump administration&#8217;s defense and intelligence priorities.
Palantir shares also <a href="https://www.benzinga.com/news/24/11/41808861/whats-going-on-with-palantir-stock-thursday">faced early pressure</a> after Jefferies downgraded the stock from Hold to Underperform, citing valuation concerns. However, the stock bounced back intraday Thursday after Palantir announced a partnership with Amazon Web Services (AWS) and Anthropic to bring advanced AI capabilities to U.S. defense and intelligence agencies. The partnership will integrate Anthropic&#8217;s Claude AI models into Palantir's AI Platform for secure government use.
PLTR Price Action: Palantir shares were up 4.60% at $58.44 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-1024x542.png" alt="" class="wp-image-638322" style="width:469px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR.png 1180w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41853996/sony-posts-upbeat-earnings-joins-tesla-upstart-doximity-fortrea-axon-enterprise-and-other-big-stocks-moving-higher-on-friday">Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday</a></li>
</ul>
Image Via Shutterstock.

PLTR

What's Going On With Palantir Stock This Week?

Throughout the last three months, 4 analysts have evaluated Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dianthus Therapeutics, revealing an average target of $46.0, a high estimate of $56.00, and a low estimate of $40.00. Marking an increase of 5.34%, the current average surpasses the previous average price target of $43.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1731099673_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Dianthus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dianthus Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dianthus Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dianthus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dianthus Therapeutics</h2>
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
<h3>Understanding the Numbers: Dianthus Therapeutics's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dianthus Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 92.26%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -945.09%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Dianthus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dianthus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Dianthus Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

DNTH

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is reportedly considering the sale of Jeppesen, a navigation unit it acquired in 2000, to reduce its $58 billion debt. <a href="https://www.bloomberg.com/news/articles/2024-11-08/boeing-is-exploring-possible-6-billion-sale-for-jeppesen-unit?srnd=homepage-americas">Bloomberg reported </a>that the company is working with an adviser on a sale that could bring in more than $6 billion. 
The unit, which provides navigation tools to airlines, has already attracted interest from many private equity firms.
The possible divestment follows CEO Kelly Ortberg's review of Boeing's assets to identify units that may no longer align with the company&#8217;s focus on core commercial aircraft production. Ortberg said in an earnings call that he's looking at "whether a business or product fits with the long-term strategy or whether it would be better off someplace else."
Ortberg also confirmed that Boeing will pay employees furloughed during the seven-week strike in Seattle, according to a <a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.">BNN Bloomberg report.</a> "We want to acknowledge your support by returning your lost pay," the CEO said in an internal memo. 
However, the company plans more job cuts to reduce costs. Boeing has already been cutting costs with hiring freezes and corporate travel reductions to handle its cash shortage.
BA Price Action: Boeing shares were up 0.48% at $151.70 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png" alt="" class="wp-image-638240" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1.png 1185w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41853052/how-much-is-nintendo-suing-palworld-for-patents-financial-details-unveiled">How Much Is Nintendo Suing Palworld For? Patents, Financial Details Unveiled</a></li>
</ul>
Image Via Shutterstock.

What's Going On With Boeing Shares Today?

Tevogen Bio Nears Finalization Of R&D And Manufacturing Expansion Deal With CD8 Technology; Secures $36M Line Of Credit To Support Operations And Long-Term Growth

Peak Bio (PKBO) has released an update to notify the public and investors about the unregistered sales of equity securities. Peak Bio, Inc. has eng...

Peak Bio Raises Capital via Convertible Promissory Notes

Peak Bio (PKBO) has released an update. Peak Bio, Inc. has successfully secured multiple rounds of financing through convertible note agreements wi...

Peak Bio Raises Over $2M Through Convertible Notes

Akari Therapeutics rises on all stock deal with Peak Bio

Akari Therapeutics rises on all-stock merger deal with Peak Bio

The latest update is out from Peak Bio (PKBO). Peak Bio, Inc. has entered into a pivotal Merger Agreement with Akari Therapeutics, leading to Peak ...

Peak Bio's Strategic Merger with Akari Therapeutics

Peak Bio (PKBO) has issued an announcement. David Rosenberg, Michael Friedman, and Stephen LaMond have abruptly resigned from their positions on th...

Peak Bio Board Reshuffle as Three Members Resign

An update from Peak Bio (PKBO) is now available. Peak Bio, Inc. has appointed Sandip Patel as a director and chair of the Audit Committee. With no ...

Peak Bio Appoints Sandip Patel as Director and Audit Chair

An update from Peak Bio (PKBO) is now available. Stephen LaMond has stepped down as the Interim CEO and COO of Peak Bio, Inc., and will transition ...

Peak Bio Announces CEO Transition and New Leadership

Peak Bio ( ($PKBO) ) has provided an update. Peak Bio, Inc. has awarded 4.15 million stock options to its key personnel, including top executives a...

Peak Bio Incentivizes Leadership with Stock Options for Growth

AKTX

PKBO

Press Releases

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Management

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Peak Bio

Ladenburg Thalmann

Comments

Peak Bio

Peak Bio (PKBO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO